Proxy Results Form 8 K

(e)

On August 27, 2024, CalciMedica, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders approved an amendment to the Company's 2023 Equity Incentive Plan (the "2023 Plan" and the 2023 Plan, as amended, the "2023 Amended Plan") to, among other things, increase the number of shares of common stock authorized for issuance under the plan by 1,500,000 shares. The 2023 Amended Plan was previously approved, subject to stockholder approval, by the Company's Board of Directors on March 28, 2024. A summary of the principal features of the 2023 Amended Plan are set forth under the heading "Proposal No. 3-To Approve an Amendment to the CalciMedica, Inc. 2023 Equity Incentive Plan" contained in the Company's definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on July 16, 2024 (the "2024 Proxy Statement"). The summaries are qualified in their entirety by reference to the 2023 Amended Plan, filed as Exhibit 10.1 to this report.